The filamentous hemagglutinin (FHA) of Bordetella pertussis was expressed in the attenuated aroA mutant of Salmonella typhimurium, SL3261, and in a strain of Escherichia coli harboring Shigella flexneri plasmid pWR110, which encodes bacterial invasiveness for epithelial cells. Expression of FHA in these strains did not interfere with their ability to invade Henle cells. Immunoglobulins A and G specific for FHA were detected in lung washes of mice following oral immunization with the live recombinant organisms; antibody levels were significantly higher than those in mice immunized with killed bacteria administered orally or intraperitoneally. Live oral vaccines carrying protective antigens of B. pertussis may be an important alternative to newgeneration component vaccines against whooping cough.
Bordetella pertussis is the etiological agent of whooping cough, an infection of the upper and lower respiratory tracts. The disease is particularly severe in young children and may lead to neurological disorders and death (45) . The incidence of whooping cough has been largely reduced by mass immunization with a heat-killed, whole-cell vaccine (11) . However, concern about the infrequent but severe neurological side effects of this vaccine (6, 25) has led to a decreased acceptance rate (47) accompanied by an increase in disease incidence (33) . New-generation vaccines composed of defined and nontoxic components are urgently needed.
Several virulence factors of B. pertussis have been considered for inclusion in defined acellular vaccines which would have reduced toxicity, and studies with animal models have highlighted pertussis toxoid and filamentous hemagglutinin (FHA) as prime candidates (20, 30) . However, acellular vaccines composed of preparations of these two proteins exhibited lower efficacy than expected in human trials, despite their ability to induce a humoral response (1, 26, 43) .
A number of vaccines that consist of live microorganisms which elicit better protection than killed organisms or cell extracts have been developed. More recently, several attenuated mutants of Salmonella spp. have been developed as delivery systems to stimulate mucosal immunity to cloned heterologous immunogens (19) . These mutants are unable to multiply extensively or cause disease in the host but do establish a self-limiting, subclinical infection and can be detected in tissues such as the liver and spleen (5, 19). Mucosal, humoral, and cell-mediated immunity to antigens expressed by these strains can be induced by oral immunization (3, 9, 10, 19, 29, 35) . Such delivery systems are, therefore, quite promising for vaccine development, and recently Salmonella typhi strains and capsule formulations suitable for oral administration have been accepted by the U.S. Food and Drug Administration for human use (22) .
A related antigen delivery system is Escherichia coli K-12 containing the virulence plasmid pWR110 of Shigella flexneri, which specifies bacterial invasion of mammalian cells (16, 17, 23, 39, 40) . This bacterium invades HeLa cells in tissue culture and produces a mild inflammatory reaction in the lamina propria in the rabbit ileal loop test (38) . Monkeys orally immunized with E. coli K-12(pWR110) expressing S. flexneri 2a surface antigens were protected against oral challenge with virulent S. flexneri 2a bacteria (12) .
Here we describe the oral immunization of mice with Salmonella typhimurium aroA and invasive E. coli hybrids expressing the 220-kDa FHA of B. pertussis and the induction of both systemic immunoglobulin G (IgG) and mucosal IgA anti-FHA antibodies.
MATERIALS AND METHODS Bacterial strains, plasmids, and media. The bacterial strains used in this work were E. coli EC538 (J. E. G. McCarthy), S. typhimurium aroA SL3261 (19) , and E. coli K-12 strain 395-1 (38) . The plasmids used in this work were pCG26 (Apr) (15) , pWR110 (Km), and R64drdll (Tcr) (17, 38, 39 40 cells. For invasiveness assays, DME containing gentamicin (100 ,ug/ml) was then added; this concentration of gentamicin killed extracellular bacteria and thereby prevented any reinfection of cells. Monolayers were incubated for an additional 3 h and then washed three times with PBS. The number of invading bacteria was determined both by selectively staining the viable intracellular microorganisms by using the method described by Pruzanski et al. (32) and by lysing the eukaryotic cells with 1 ml of ice-cold water added to each well and then determining the viable count on Luria agar plates.
DNA manipulations. Plasmid DNA isolation and transformation were performed as described by Sambrook et al. (36) . Conjugal transfer of pWR11O (Kmr) to E. coli EC538 was accomplished with the mobilizing helper plasmid R64drdll (Tcr), as previously described by Sansonetti et al. (38, 39) .
Mouse immunization. Six-to seven-week-old female BALB/c mice were immunized and caged separately. Mice were immunized as shown in Table 1 . Groups a to i were immunized with one dose on day 0 and boosted with an identical dose 24 days later. The animals were sacrificed 10 days after the booster, and the samples were collected. For groups j and k, only 1 Groups a to i were immunized twice (days 0 and 24) and sacrificed 10 days after the booster; groups j and k were immunized once and sacrificed 24 days later.
b Experiments with these groups were repeated with independently prepared vaccines and the same number of mice (five and six, respectively). Results in Fig. 2 refer to averages from both experiments.
ice-cold PBS containing 2 mM phenylmethylsulfonylfluoride as the protease inhibitor. About 0.5 ml of lung wash was recovered from each mouse, centrifuged at 4°C at 3,000 x g for 5 min to remove debris, and stored at -20°C.
Immunological techniques. Monoclonal antibody P12H3 against FHA was kindly provided by C. Parker (13) . For Western blot experiments, whole-cell extracts of bacteria were mixed with loading buffer (36) in a ratio of 1:1, and approximately 50 ,ug of protein was electrophoresed according to the procedure of Laemmli (21) by using a 3.85% acrylamide stacking gel and a 10% acrylamide separating gel. Blotting was carried out essentially as described by Burnette (4). Proteins were transferred to a nitrocellulose membrane with a semidry transfer cell by using 25 mM Tris-192 mM glycine-20% methanol, pH 8.3, as the transfer buffer and a 10% solution of 0.3% fat milk in PBS, pH 7.4, as the blocking reagent. The blocked membrane was incubated for 2 h with the first antibody (hybridoma P12H3 supernatants diluted 1:20 in PBS), washed three times with PBS, and incubated for 1 h with Bio-Rad horseradish peroxidase-conjugated goat anti-mouse IgG. Membranes were washed and developed with 4-chloro-1-naphthol as a substrate. Prestained molecular weight markers were purchased from Bio-Rad.
For 
RESULTS
Expression of recombinant nonfusion FHA in S. typhimurium and E. coli. The construction of recombinant S. typhimurium aroA SL3261(pCG26) and E. coli EC538(pCG26) strains was described previously (15) . In these strains, nonfusion recombinant FHA (200 to 220 kDa) is either produced as a soluble cytoplasmic protein (EC538) or deposited in inclusion bodies (SL3261). The wild-type and the recombinant protein have similar migration patterns on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
The pWR11O (Kmr) 140-MDa virulence plasmid encoding the invasive phenotype of S. flexneri was mobilized into EC538(pCG26) (Apr) by using the helper plasmid R64drdll (Tcr) and selecting for Apr Kmr transconjugants to produce EC538(pCG26, pWR110). In both recombinant strains, SL3261(pCG26) and EC538(pCG26, pWR110), the FHA gene is under the control of the thermoregulated tandem PR and PL promoters and the translation initiation region of the E. coli atpE gene. The first 15 codons of the FHA gene had been engineered to reduce mRNA secondary structure in the NH2-terminal coding region. Expression is repressed at 30°C and induced at temperatures above 34°C. Western blot analysis (Fig. 1 ) demonstrated that in both SL3261 and In vitro adhesiveness and invasiveness of strains used in the vaccination protocols. The results presented in Table 2 show that the presence of hybrid plasmid pCG26 did not alter the adhesive or invasive properties of the carrier strains. E. coli harboring pWR110 adhered more efficiently to Henle cells than did the Salmonella strain, which in turn adhered more efficiently than E. coli lacking pWR110. The two methods used to assess invasiveness gave comparable results. No viable bacteria were isolated from invasion assays with E. coli lacking pWR110, and the few Henle cells observed microscopically to contain such bacteria may be artifacts. E. coli bacteria containing plasmid pWR110 were considerably more invasive than Salmonella bacteria. This is probably due at least in part to the inability of S. typhimurium to replicate in vivo as a result of its aroA mutation. However, the invasiveness of S. typhimurium was considerably greater when centrifugation was used to facilitate contact between bacteria and host cells (results not shown). The relevance of this to the in vivo situation is not, however, clear.
Antibody responses specific for B. pertussis FHA in vaccinated mice. Both FHA delivery systems elicited specific serum and mucosal immune responses (Fig. 2) . Some correlation between the ability of carrier strains to invade Henle cells in vitro and their ability to stimulate antibody production in the lungs was observed. Higher immune responses from live vaccines are evident from a comparison of the immune responses induced by intraperitoneal (i.p.) immunization (compare group d with groups g and i in Table 1 and Fig. 2 ) and peroral immunization (compare groups b and c in Table 1 and Fig. 2) . Moreover, IgA could be detected in the lungs only when the peroral route was used for delivering S. Delivery systems based on E. coli(pWR110) offer more flexibility than Salmonella systems. The genetics of S. typhimurium is not as well developed as that of E. coli, and it is easier to optimize expression of recombinant antigens in E. coli and then transfer in the necessary invasion genes. Although we were fortunate in obtaining good expression of FHA in the one Salmonella strain selected, we found expression in E. coli to be highly strain dependent (15) . Obviously, plasmids such as pWR110 which specify antibiotic resistance are unacceptable in human vaccines, but the existence of versatile transposon cloning vectors lacking antibiotic resistance markers that can stably integrate cloned genes into host chromosomes (18) will enable the cloning of invasion genes (23) and their insertion into the chromosomes of selected antigen carrier strains. The stability of immunogencoding sequences and the absence of antibiotic resistance selection markers are crucial features of live vaccines. To achieve these goals, we are currently working on transposon-mediated chromosomal integration (18) of the FHA gene and the necessary expression signals needed to achieve high-level in vivo expression of FHA, by using an approach that previously gave good expression of the pertussis toxin operon in Bordetella bronchiseptica (46) .
Recently, Parker and coworkers (27, 31) orally immunized mice with Salmonella bacteria expressing truncated FHA by using a host-vector system which causes release of the intracellular antigen and prevents loss of hybrid plasmids in vivo. Although this group was able to detect FHA-specific IgG in serum, they failed to detect specific IgA in lung washes. The strong mucosal immune responses measured in our experiments may be due either to a higher level of expression of FHA in pCG26-carrying bacteria or to the particular delivery strains used in this study. In addition, pCG26 specifies the entire 220-kDa protein, and it is possible that the native protein is more immunogenic than the truncated forms expressed in previous studies (27, 31) .
The role of cell-mediated immunity in protection against B. pertussis is not known, although a cell-mediated response to several B. pertussis antigens, including FHA, has been demonstrated in convalescent patients (8, 14) . As Salmonella-expressing heterologous antigens are known to induce cell-mediated immunity (3, 35) , it will be of interest to determine whether the delivery systems used in this study induce cell-mediated mucosal responses to FHA in addition to an antibody response.
It is not known whether vaccines based solely on FHA can offer sufficient protection in humans against B. pertussis infection (26, 43, 44) . However, the potential of these carrier systems to stimulate a strong mucosal immune response to B. pertussis antigens that we demonstrate here will encourage the construction of carrier strains expressing more than one B. pertussis antigen. The recent successful oral immunization against tetanus in mice by using the SL3261 carrier strain (10) supports this thesis and opens up new perspectives for the development of oral attenuated multivalent vaccines that could replace the old DTP vaccine in vaccination regimens.
